Results 71 to 80 of about 26,436 (212)
Cancer Management and Research, 2021 Fuqun Wei,1,* Qizhen Huang,2,* Jian He,1 Liuping Luo,1 Yongyi Zeng1 1Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China; 2Department of Radiation ...
Wei F, Huang Q, He J, Luo L, Zeng Y
doaj
Interdisciplinary Medicine, EarlyView.Integrated multi‐omics reveals that CD36‐mediated lipid overload in PBMCs drives T cell exhaustion via sub‐lethal ferroptotic stress and AKT suppression. This systemic metabolic signature serves as a robust predictor of immunotherapy response in HCC, suggesting that modulating lipid metabolism can rescue immune fitness.
Ying Zhu +6 more
wiley +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu +2 more
wiley +1 more source
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment
Stephen L. Chan, Landon L. Chan
core +1 more source
Lenvatinib: Role in thyroid cancer and other solid tumors [PDF]
, 2016 Despite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain poor. Treatment of advanced, progressive disease remains challenging, with limited treatment options. Small-molecule tyrosine kinase inhibitors, including vandetanib,
Cabanillas, Maria E. +3 more
core +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo +9 more
wiley +1 more source
, 2019 Monica Capozzi,1 Chiara De Divitiis,2 Alessandro Ottaiano,3 Claudia von Arx,4 Stefania Scala,5 Fabiana Tatangelo,6 Paolo Delrio,1 Salvatore Tafuto11Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS - Fondazione “G.
von Arx C +7 more
core
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy‐based treatment. This single‐center retrospective study included 237 patients who received first‐line toripalimab plus axitinib therapy.
Yun‐Feng Wu +4 more
wiley +1 more source
Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma
The Laryngoscope, EarlyView.We investigated the mutational landscape and prognostic implications of recurrent/metastatic papillary thyroid carcinoma using nationwide C‐CAT data from 348 patients. CDKN2A, KMT2D, and concurrent TERT/BRAF mutations were independently associated with poorer overall survival, highlighting the potential prognostic value of comprehensive genomic ...
Hiromi Nagano +3 more
wiley +1 more source
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
, 2019 Nicola Personeni,1,2 Tiziana Pressiani,1 Lorenza Rimassa1 1Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center – IRCCS, Rozzano 20089, Milan, Italy; 2Department of Biomedical Sciences, Humanitas ...
Personeni N, Rimassa L, Pressiani T
core